Background Using non-statin lipid-modifying agents in combination with statin therapy provides additional benefits for cardiovascular disease (CVD) risk reduction, but their value for money has only been evaluated in high-income countries (HICs). Furthermore, studies mainly derive effectiveness data from a single trial or older meta-analyses. Objectives Our study used data from the most recent network meta-analysis (NMA) and local parameters to assess the cost effectiveness of non-statin agents in statin-treated patients with a history of CVD. Methods A published Markov model was adopted to investigate lifetime outcomes: (1) number of recurrent CVD events prevented, (2) quality-adjusted life-years (QALYs) gained, (3) costs and (4) incremental cost-effectiveness ratios (ICERs) of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe added to statin therapy. Event rates and effectiveness inputs were obtained from the NMA. Cost and utility data were gathered from published studies conducted in Thailand. A series of sensitivity analyses were performed. Results Patients receiving PCSK9i and ezetimibe experienced fewer recurrent CVD events (number needed to treat [NNT] 17 and 30) and more QALYs (0.168 and 0.096 QALYs gained per person). However, under the societal perspective and at current acquisition costs in 2018, ICERs of both agents were $US1,223,995 and 27,361 per QALY gained, respectively. Based on threshold analyses, the costs need to be reduced by 97 and 85%, respectively, for PCSK9i and ezetimibe to be cost-effective. Conclusions Despite the proven effectiveness of PCSK9i and ezetimibe, the costs of these agents need to reduce to a much greater extent than in HICs to be cost-effective in Thailand.
Introduction
Cardiovascular diseases (CVDs), especially myocardial infarction (MI) and stroke, have been the leading causes of death across the world. The CVD situation is evidently more critical for low-and middle-income countries (LMICs), where approximately 80% of all cardiovascular-related deaths worldwide are observed [1] and the number of lifeyears lost due to premature CVD death continues to increase [2] . Patients with a history of CVD are at particularly high risk of recurrent CVD and death. Thus, implementing secondary prevention strategies to prevent the recurrence of CVD events is critical. One of the strategies recommended by clinical practice guidelines [3, 4] is the use of lipid-modifying agents, especially statins, to reduce levels of low-density lipoprotein cholesterol (LDL-C). Based on a landmark meta-analysis [5] , a reduction of 1 mmol/L in LDL-C level with statin therapy is associated with a 23% decrease in the risk of developing major vascular events (relative risk [RR] 0.77; 95% confidence interval [CI] 0.71-0.84). Most international guidelines currently recommend either a targeted percentage of LDL-C reduction or a specific LDL-C level based on individual CVD risk. However, a significant proportion of patients are unable to achieve their lipid goal using statins alone. Hence, adding non-statin lipid-modifying agents to statin therapy may be reasonable in this situation [6] [7] [8] .
Several studies have investigated the cost effectiveness of non-statin lipid-modifying agents when used in combination with statin therapy [9] . However, all of them have been conducted in high-income countries (HICs), including the USA [10, 11] , Norway [12] , Spain [13] and Australia [14] . Significant differences in healthcare structure and economic status limit the application of findings from HICs to LMICs. In addition, the published studies derive effectiveness inputs from a single randomized controlled trial (RCT) [14] or older systematic reviews and meta-analyses [10] [11] [12] [13] . A recent systematic review and network meta-analysis (NMA) of 67 RCTs on this topic [15] provided comprehensive event rates and pooled effectiveness data that increased the generalizability of findings. Therefore, our study aimed to assess the cost effectiveness of non-statin lipid-modifying agents in statin-treated patients with a history of CVD using data from the NMA and local parameters from studies conducted in Thailand to provide an LMIC context.
Methods

Overall Description
Our study adopted a Markov state-transition model ( Fig. 1) developed by Kumar et al. [14] to simulate the progression of patients with existing CVD, comprising MI and stroke. The model conceptualized a cohort with existing CVD into three health states: (1) no recurrent CVD, (2) recurrent CVD and (3) dead. With each 1-year cycle, patients in the no recurrent CVD state could develop non-fatal recurrent CVD and move to the recurrent CVD state. Alternatively, they could die from either CVD or other causes. The same transition patterns were applied to patients in the recurrent CVD state.
A cost-effectiveness analysis was performed to estimate costs and health outcomes of non-statin lipid-modifying agents added to statin therapy compared with statins alone. Non-statin lipid-modifying agents considered in this analysis included proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and ezetimibe. These agents were recommended in the 2018 American College of Cardiology/ American Heart Association (ACC/AHA) guideline on the management of blood cholesterol as they may be useful in combination with statin therapy [3] . Outcomes of interest were (1) number of CVD events prevented, as number needed to treat (NNT); (2) quality-adjusted life-years (QALYs); (3) costs; and (4) incremental cost-effectiveness ratios (ICERs). To capture long-term costs and effectiveness, a Thai cohort of patients with CVD was followed from the age of 62 years [16] for their lifetime. In line with health technology assessment (HTA) guidelines in Thailand [17] , the discount rate of 3% per annum was applied to both costs and benefits, and the study was assessed from both the health system perspective and the societal perspective.
Input Parameters
Epidemiological data were obtained from the most recent systematic review and NMA of 67 RCTs, comprising 259,429 patients, comparing non-statin lipid-modifying agents among statin-treated patients [15] . Costs and health utilities were based on published studies conducted in Thailand. All input parameters and sources of information used in the model are summarized in Table 1 . Full details of searching and selection are provided in Appendix 3 in the Electronic Supplementary Material (ESM).
Likelihood of Events
We used subgroup analyses of the NMA [15] , in which only RCTs in secondary prevention settings were considered, to derive all transition probabilities (e.g., probability of developing non-fatal CVD, developing fatal CVD and dying from any causes) as well as the RRs of the intervention's effectiveness compared with statin background therapy. As observed in the Thai population, 10-year increases in age were associated with a 2.7 times higher chance of vascular mortality (hazard ratio [HR] 2.7; 95% CI 1.5-4.8) [18] . Thus, the transition probability of developing fatal CVD was then inflated with this HR to reflect age-related changes in the Thai population. Similarly, the transition probability of dying from any causes was also inflated with each subsequent cycle according to age-related changes in mortality rates observed in Thai mortality data [19] . We estimated the probability of dying from other causes by subtracting the probability of dying from any causes with the probability of developing fatal CVD. Since our study considered both MI and stroke for CVD events, the proportion of MI and stroke events was also derived from the NMA [15] to adjust the costs and outcomes of MI and stroke, respectively. See Appendix 1 in the ESM for details of the calculations of likelihood of events.
Cost Parameters
Costs of the secondary prevention population who experienced no recurrent CVD (costs of pre-event), costs of non-fatal MI, costs of fatal MI and direct non-medical costs were derived from Anukooksawat et al. [20] . This study used data from Thai Acute Coronary Syndrome (ACS) registry to estimate the lifetime costs of ACS. Medical records of 330 patients with ACS were used to calculate the pre-event and MI-related costs (Appendix 4 in the ESM), and interview records for 193 patients with ACS were used to estimate direct non-medical costs.
The costs of non-fatal stroke and fatal stroke were obtained from Tamteeranon et al. [21] . This study investigated the cost effectiveness of statins used in primary cardiovascular disease prevention among the Thai population, and stroke-related costs were reportedly derived from a cost study conducted at Prasat Neurological Institute in Thailand [22] . This study retrospectively collected healthcare resource utilization from 354 medical charts and estimated strokerelated costs using a micro-costing approach.
Treatment costs for statins and ezetimibe were based on the national drug price list [23] from the Drug and Medical Supply Information Center, Thailand Ministry of Public Health. However, as PCSK9i were not included in the national drug list, we obtained their prices directly from Amgen Inc. and Sanofi-Aventis in Thailand. Details of treatment costs and dosage regimens for all interventions are provided in Appendix 2 in the ESM.
Direct non-medical costs were not captured in the healthcare perspective analysis but were included for the societal perspective. In line with recommendations in the Thai guidelines for HTA [17, 24] , indirect costs were not included in the cost-utility analysis.
Direct medical costs included the costs incurred by hospital visits and medications related to MI and stroke, whereas direct non-medical costs were valued from transportation usage and caregiver's time. All expenses incurred during the first year of CVD events were defined as acute costs, whereas those in each of the following years were considered chronic costs. Cost data from the published Thai studies were inflated to year 2018 values using the medical-care consumer price index [25] . The average market exchange rate in 2018 was $US1 = 32.0390 Thai Baht (THB) [26] .
Health Utility Data
Our study obtained country-specific health utility data for the secondary CVD prevention population from Jarungsuccess and Taerakun [27] . These authors assessed patients who recovered from CVD, including MI and stroke, using the EuroQoL-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire. Annual utility decrements of recurrent MI and stroke, originally derived from systematic reviews for the HTA of statins for primary CVD prevention in Thailand [21, 28] , were applied once after each of the recurrent events to penalize baseline health utilities.
Base-Case Analysis
We estimated the expected lifetime costs and outcomes for PCKS9i and ezetimibe added to statin therapy compared with no treatment added. We determined the cost effectiveness of both alternatives based on the willingnessto-pay (WTP) threshold of THB160,000/QALY gained ($US4994/QALY gained) as recommended by the Thai Health Economic Working Group for drug listing in the National List of Essential Medicines [29] . 
Sensitivity Analyses
We conducted a series of sensitivity analyses to test model assumptions and identify key determinants of the ICERs. One-way sensitivity analyses were performed by varying the following variables while keeping other variables constant: probabilities, RRs, costs, a utility value and discount rates. The upper and lower ranges of the RRs and a utility value were available from the original articles (Table 1) . However, the ranges of probabilities were set at the mean ± standard error (SE), and those of costs were ± 20% from their mean values. For discount rates, 0 and 6% per annum were applied to both costs and outcomes as lower and upper ranges, respectively [17] .
Results of the one-way sensitivity analyses are displayed as tornado diagrams.
In addition, several scenario analyses were carried out as follows: (1) increasing the probability of developing nonfatal CVD by age; (2) varying treatment effects (RRs) on the probability of developing non-fatal CVD to 0.7, 0.6 and 0.5; (3) varying the time horizon to 2, 5, 10 and 20 years; and (4) varying discount rates for costs to 4% and outcomes to 2% per annum [30] . We also examined what acquisition costs for PCSK9i and ezetimibe would provide cost-effective results in threshold analyses.
Furthermore, probabilistic sensitivity analyses (PSA) were undertaken to simultaneously examine the impact that uncertainties, inherent in all input parameters, may have on study results using the Monte Carlo simulation. Each input parameter was assigned with a probability distribution to reflect their feasible ranges. Beta, gamma and log-normal distributions were applied to probabilities and a utility value, costs and RRs, respectively. In total, 1000 iterations were performed. Results of the PSA are presented as cost-effectiveness scatterplots and cost-effectiveness acceptability curves (CEACs).
Model Validation
Our model was entirely constructed using Microsoft Excel 2013. A peer-reviewed model [14] was adopted and crosschecked by clinicians in Thailand to ensure that the model was consistent with the natural history of the disease, practical in a local context and capable of generating outputs that hold face validity [31] . Technical validity was also checked in each step of calculations to ensure that our model did not contain any coding or calculation errors [31] .
Results
Base-Case Analysis
Throughout the simulated lifetime of 1000 individuals in the model, PCSK9i and ezetimibe prevented 58 and 33 recurrent CVD events, respectively. These equated to NNTs of 17 and 30, respectively. Under the societal perspective, adding PCSK9i to statin therapy saved 168 QALYs but was associated with a THB2920 million ($US91 million) increase in total costs. Adding ezetimibe to statin therapy produced 96 QALYs but was associated with an increase in total costs of THB83 million ($US3 million). The ICERs of PCSK9i and ezetimibe were THB39,215,587/QALY gained ($US1,223,995/QALY gained) and THB876,634/QALY gained ($US27,361/ QALY gained), respectively. Thus, both alternatives failed to yield ICERs below the cost-effectiveness threshold of THB160,000/QALY gained ($US4994/QALY gained). Results of all outcomes of interest are presented in Table 2 .
One-Way Sensitivity Analyses
Under the societal perspective, the one-way sensitivity analyses (Figs. 2 and 3) showed that the uncertainty around the RR of dying from any cause caused the largest variation in PCSK9i ICER, from THB8.9 million/QALY gained ($US279,077/QALY gained) to being dominated, followed by the RR of developing fatal CVD. Similarly, the uncertainty around the RR of dying from any cause led to the greatest variation in ezetimibe ICER, from THB285,149/ QALY gained ($US8900/QALY gained) to being dominated, followed by the RR of developing fatal CVD. All the remaining parameters appeared to have moderate to minimal impacts on the cost-effectiveness results for both PCSK9i and ezetimibe.
Scenario Analyses
Scenario analyses (Table 3) showed that results were very robust in all scenarios examined, indicating that neither PCSK9i nor ezetimibe was cost-effective.
Probabilistic Sensitivity Analyses
Under the societal perspective, the cost-effectiveness scatterplots (Fig. 4) , generated from 1000 Monte Carlo simulations, showed that 14.5% of the PCSK9i ICERs and 31.8% of the ezetimibe ICERs were located in the left-upper quadrant, indicating that both add-on interventions were less effective and more expensive. Moreover, if the WTP threshold was set at THB160,000/QALY gained ($US4994/QALY gained), the CEAC (Fig. 5) revealed that PCSK9i would have no chance of being cost-effective, whereas ezetimibe would have a 0.2% probability of being cost-effective.
Threshold Analyses
At their current acquisition costs, both PCSK9i and ezetimibe added to statin therapy were less likely to be costeffective. According to our threshold analysis under the societal perspective, the costs of PCSK9i and ezetimibe would have to reduce by 97 and 85%, respectively, to be considered cost-effective.
Discussion
This is the first cost-effectiveness study that investigates the value for money of non-statin lipid-modifying agents used in combination with statin therapy compared with statins alone in Thailand. The base-case analysis suggests that, even though PCSK9i and ezetimibe are effective for the prevention of recurrent CVD events, they are not cost-effective at their current acquisition costs based on the WTP threshold in Thailand. These findings are consistent with those from sensitivity and scenario analyses, reflecting the robustness of the model. Importantly, threshold analyses reveal that substantial reductions in the costs of PCSK9i and ezetimibe are required for them to be considered cost-effective in a Thai context. The economic value of non-statin lipid-modifying agents, especially PCSK9i, has been assessed in several cost-effectiveness studies in HICs. For example, in the USA, where most of the studies are conducted, the ICERs of PCSK9i added to statin therapy are reported to range from $US141,699 [32] to 1,336,211 [33] per QALY gained when (25, 112) compared with statins alone for secondary CVD prevention.
To be cost-effective, the acquisition cost of PCSK9i must decrease by 33% [34] to 88% [33] . These existing findings are consistent with those of our study, which indicate that the use of PCSK9i results in an ICER of $US542,484/QALY gained. However, the cost of PCSK9i needs to reduce to a greater extent than in the USA for it to be cost-effective (> 99%) in Thailand. Recent Trump administration policies regarding prescription drug price controls exert a direct influence on costly medications, including PCSK9i. In the USA, pharmaceutical companies, who hold the patent for PCSK9i, have already responded to the policy by reducing the price of PCSK9i by approximately 60% [35] . This magnitude of price reduction may be sufficient to make PCSK9i cost-effective in the USA, but a much greater price reduction would be required for it to be cost-effective in countries with a lower per capita gross domestic product, such as Thailand and other LMICs.
The major strength of our study stemmed from the use of key model parameters derived from the most recent systematic review and NMA on this topic [15] . Unlike the existing cost-effectiveness studies on non-statin lipid-modifying agents, whose inputs depended on data from a single RCT or older meta-analyses, our study improves the cost-effectiveness findings to be more reflective of general secondary preventive settings. Moreover, our findings are in agreement with the 2018 ACC/AHA guidelines on the management of blood cholesterol [3] , which state that, despite their low value for money, PCSK9i and ezetimibe may reasonably be considered for patients with CVD who are on maximally tolerated statin therapy but have not yet achieved desirable LDL-C levels. Therefore, our study provides additional local evidence, which further strengthens the recommendations provided in the guideline.
Nonetheless, several limitations are worth addressing. First, our study was limited to cost effectiveness in a nonspecific secondary prevention setting. Using non-statin lipidmodifying agents in combination with statin therapy may provide more cost-effective results when used in high-risk patients, such as those with familial hypercholesterolemia (FH). However, because evidence in the FH population is sparse, as reported in the NMA [15] , which results in inaccurate treatment effects, we did not investigate the use of non-statin agents in this specific population. Second, we did not consider adverse events and discontinuations of non-statin agents in our analysis. However, the safety and tolerability profiles for both PCSK9i [6, 7] and ezetimibe [36] when used in addition to statin therapy do not differ from the statin monotherapy profiles. Third, we considered only MI and stroke to represent CVDs in our analysis, these PCSK9i, QALY quality-adjusted life-year, THB Thai baht being the predominant forms of atherosclerotic CVD that lipid-lowering therapy prevents. Other types of CVD may be indirectly affected by lipid-lowering therapy (particularly heart failure, which is a complication of MI), but their inclusion would have made the modelled analyses very complex. Fourth, to make our cost-effectiveness findings reflect the local context, the risk of vascular mortality by age [18] and cost parameters [20, 21] were derived from the studies available in Thailand. Although these studies were conducted in the last 10 years, they have the advantage of being of high quality, and the cost studies [20, 21] are cited in a number of related economic evaluation studies [21, 28, 37] . Nevertheless, we identify this as an evidence gap that calls for the generation of further research that could serve as better input parameters for future economic evaluations. Finally, in Thailand, policy makers generally require budget impact analyses (BIA), in addition to efficacy, safety and cost-effectiveness evidence, when determining the adoption of any treatment in the national list of essential medicines. However, we did not include a BIA in our study. Future studies should consider including a BIA to fully serve the needs of policy makers.
Conclusions
According to our analysis, PCSK9i and ezetimibe are effective at preventing recurrent CVD events and lead to higher QALYs when used in combination with statin therapy. However, these agents will only be cost-effective if their acquisition costs are reduced by 97 and 85%, respectively. The cost reduction required for PCSK9i to become cost-effective is substantially higher than that reported in studies conducted in HICs.
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